Press Releases

SALT LAKE CITY, July 1, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its

Recursion to open office space within Mila and build machine learning team to focus on some of drug discovery's most challenging problems MONTRÉAL, June 23, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological

The company aims to hire up to 50 people by the end of 2021 across disciplines of data science, machine learning, engineering, product management and computational biology. TORONTO, June 15, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by

Lux Capital, Mubadala Capital, Obvious Ventures, and DCVC among founding group supporting underrepresented founders building next-generation healthcare companies SALT LAKE CITY, June 8, 2021 / PRNewswire / -- Altitude Lab today announced the launch of its Investor Coalition, a partnered network of

SALT LAKE CITY, May 25, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company

- Strengthened balance sheet with the completion of a successful IPO - Purchased, built, and activated BioHive-1, reportedly the 58th most powerful supercomputer in the world, to accelerate our drug discovery process - Continued development of internal pipeline and partnership programs remain on

SALT LAKE CITY, April 21, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we")  announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to

SALT LAKE CITY, April 16, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common

Former Goldman Sachs executive to serve as Chairman of Recursion's Board, effective immediately SALT LAKE CITY, March 1, 2021 / PRNewswire / --  Recursion , a digital biology company industrializing drug discovery, today announced the appointment of R. Martin Chavez as Chairman of its Board of

Former VP & Assistant General Counsel at Pfizer to join Recursion's executive team SALT LAKE CITY, Feb. 18, 2021 / PRNewswire / --  Recursion , a biotechnology company scaling more like a technology company, today announced the appointment of Louisa Daniels, J.D., MBA as its Chief Legal Officer and